Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

AMRI signs Huntington’s disease research deal with CHDI Foundation
June 2009
SHARING OPTIONS:

ALBANY, N.Y.—AMRI and CHDI Foundation Inc., a non-profit organization pursuing drugs that delay or slow Huntington's disease (HD), announced in May that they will collaborate on the discovery of new therapeutic agents for the treatment of this disease. Under the agreement, AMRI will test samples from its compound collection against several JNK kinases. These kinases may be implicated in the progression of HD. AMRI will use its expertise in computer-aided drug discovery (CADD), biological assay development and high-throughput screening for this project. Financial terms of the deal were not disclosed.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.